entertainment -WSS

entertainment

author：knowledge 2025-08-18 11:33:09 - browse：77

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Study: Black kids more likely to die after surgery than white kids

WSS

Histogen: Failed biotech offers rare public look inside

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

A virus, fished out of a lake, may have saved a man’s life

Pancreatic cancer is often deadly, but new discoveries are raising hope

What to expect at HLTH 2023, the health care industry conference

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

focus

entertainment

focus

Anesthesiologist group: stop taking Ozempic before surgery

Multiple sclerosis has subtypes with different best treatments: study

Guidelines to prevent youth baseball injuries need more muscle

A virus, fished out of a lake, may have saved a man’s life

Novavax promises a turnaround & Lilly roils the obesity market

What to expect at HLTH 2023, the health care industry conference

Peter Hotez and the public health issue of online harassment

The future of health care in the House

Psychedelics group wrestles with new pharma identity

Liquid biopsy for lung cancer is launched by Delfi

knowledge

A virus, fished out of a lake, may have saved a man’s life

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Why Charlie Gard's case is so disturbing to Americans

Analysis of telehealth claims data suggest service duplication

Medicare Advantage 2025 payments will dip, Biden administration says

Bird flu in dairy cattle: New measures to control spread to humans

hotspot

entertainment

hotspot

entertainment